Lv41
490 积分 2024-11-24 加入
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
1个月前
已完结
Successful Alectinib Treatment Administered by Mixing With a Soft Diet in a Patient With Non–Small-Cell Lung Cancer With Severe Dysphagia
1个月前
已完结
Immune Checkpoint Inhibitor-Induced Psoriasis
2个月前
已完结
Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
2个月前
已完结
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
2个月前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
2个月前
已完结
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
3个月前
已完结
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
3个月前
已完结
Correlation between irAEs and Survival Outcomes in Patients with ES-SCLC Treated with First-Line Chemoimmunotherapy
3个月前
已完结
Enteral tube administration of oral chemotherapy drugs
3个月前
已完结
皖公网安备34019202002308
